Potential role of estrogen in the pathobiology and prevention of Alzheimer's disease

American Journal of Translational Research

Volumn 1, Issue 2, 2009, Pages 131-147

  Wharton, Whitney ^a,b   Gleason, Carey E ^a,b   Lorenze, Katelin R ^a,b   Markgraft, Tamara S ^a,b   Ries, Michele L ^a,b   Carlsson, Cynthia M ^a,b   Asthana, Sanjay ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Cognition; Estrogen; Estrogen therapy; Hormone therapy; Postmenopausal cognition; Women's health initiative

Indexed keywords

ACETYLCHOLINE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; CATECHOLAMINE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MEDROXYPROGESTERONE; PLACEBO; SEROTONIN;

ALZHEIMER DISEASE; BLOOD VESSEL FUNCTION; BRAIN ATROPHY; BRAIN BLOOD FLOW; BRAIN INJURY; BRAIN ISCHEMIA; CELL LOSS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; ESTROGEN ACTIVITY; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; HUMAN; MEMORY; MENOPAUSE; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PRIMARY PREVENTION; PROTEIN AGGREGATION; PYRAMIDAL NERVE CELL; REVIEW; RISK REDUCTION; TASK PERFORMANCE; TRAUMATIC BRAIN INJURY; TREATMENT RESPONSE;

EID: 77953458797     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (170)

1. Jorm AF, Dear KB and Burgess NM. Projections of future numbers of dementia cases in Australia with and without prevention. Aust N Z J Psychiatry 2005; 39: 959-963.
2. Hebert LE, Scherr PA, Bienias JL, Bennett DA and Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119-1122.
3. LeBlanc ES, Janowsky J, Chan BK and Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. Jama 2001; 285: 1489-1499.
4. Brann DW, Dhandapani K, Wakade C, Mahesh VB and Khan MM. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids 2007; 72: 381-405.
5. Miller MM, Monjan AA and Buckholtz NS. Estrogen replacement therapy for the potential treatment or prevention of Alzheimer's disease. Ann N Y Acad Sci 2001; 949: 223-234.
6. Hogervorst E, Williams J, Budge M, Riedel W and Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience 2000; 101: 485-512.
7. Fillit HM. The role of hormone replacement therapy in the prevention of Alzheimer disease. Arch Intern Med 2002; 162: 1934-1942.
8. Gleason CE, Cholerton B, Carlsson CM, Johnson SC and Asthana S. Neuroprotective effects of female sex steroids in humans: current controversies and future directions. Cell Mol Life Sci 2005; 62: 299-312.
9. Nilsen J and Brinton RD. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 2002; 143: 205-212.
10. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC and Breitner JC. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. Jama 2002; 288: 2123-2129.
11. Resnick SM and Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical time. Jama 2002; 288: 2170-2172.
12. Brinton RD. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Ann N Y Acad Sci 2005; 1052: 57-74.
13. Yaffe K, Sawaya G, Lieberburg I and Grady D. Estrogen therapy in postmenopausal women: Effects on cognitive function and dementia. JAMA 1998; 279: 688-695.
14. Brinton RD. Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. Adv Drug Deliv Rev 2008; 60: 1504-1511.
15. Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA and Plymate SR. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology 2001; 57: 605-612.
16. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. Jama 2002; 288: 321-333.
17. Espeland MA, Rapp SR, Shumaker SA, Brunner R, Manson JE, Sherwin BB, Hsia J, Margolis KL, Hogan PE, Wallace R, Dailey M, Freeman R and Hays J. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. Jama 2004; 291: 2959-2968.
18. Resnick SM, Maki PM, Rapp SR, Espeland MA, Brunner R, Coker LH, Granek IA, Hogan P, Ockene JK and Shumaker SA. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 2006; 91: 1802-1810.
19. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H and Mayeux R. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-432.
20. Henderson V, Paganini-Hill A, Emanuel C, Dunn M and Buckwalter J. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994; 51: 896-900.
21. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle DD and Metter E. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997; 48: 1517-1521.
22. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K and Coker LH. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. Jama 2004; 291: 2947-2958.
23. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN, 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S and Wactawski-Wende J. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. Jama 2003; 289: 2651-2662.
24. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M and Bowen D. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. Jama 2003; 289: 2663-2672.
25. Krug R, Born J and Rasch B. A 3-day estrogen treatment improves prefrontal cortex-dependent cognitive function in postmenopausal women. Psychoneuroendocrinology 2006; 31: 965-975.
26. Keenan PA, Ezzat WH, Ginsburg K and Moore GJ. Prefrontal cortex as the site of estrogen's effect on cognition. Psychoneuroendocrinology 2001; 26: 577-590.
27. Gleason CE, Schmitz TW, Hess T, Koscik RL, Trivedi MA, Ries ML, Carlsson CM, Sager MA, Asthana S and Johnson SC. Hormone effects on fMRI and cognitive measures of encoding: importance of hormone preparation. Neurology 2006; 67: 2039-2041.
28. Lokken KL and Ferraro FR. The relationship between menopausal status, phase of menstrual cycle, and replacement estrogen on cognition in healthy women without dementia. J Psychol 2006; 140: 533-547.
29. Stephens C, Bristow V and Pachana NA. HRT and everyday memory at menopause: a comparison of two samples of mid-aged women. Women Health 2006; 43: 37-57.
30. Yonker JE, Adolfsson R, Eriksson E, Hellstrand M, Nilsson LG and Herlitz A. Verified hormone therapy improves episodic memory performance in healthy postmenopausal women. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn 2006; 13: 291-307.
31. Maki PM, Zonderman AB and Resnick SM. Enhanced verbal memory in nondemented elderly women receiving hormone-replacement therapy. Am J Psychiatry 2001; 158: 227-233.
32. Smith YR, Giordani B, Lajiness-O'Neill R and Zubieta JK. Long-term estrogen replacement is associated with improved nonverbal memory and attentional measures in postmenopausal women. Fertil Steril 2001; 76: 1101-1107.
33. Ghidoni R, Boccardi M, Benussi L, Testa C, Villa A, Pievani M, Gigola L, Sabattoli F, Barbiero L, Frisoni GB and Binetti G. Effects of estrogens on cognition and brain morphology: involvement of the cerebellum. Maturitas 2006; 54: 222-228.
34. Bhavnani BR. Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. J Steroid Biochem Mol Biol 2003; 85: 473-482.
35. Yaffe K. Hormone therapy and the brain: Deja vu all over agin. JAMA 2003; 289: 2717-2719.
36. Bhavnani BR, Nisker JA, Martin J, Aletebi F, Watson L and Milne JK. Comparison of pharmacokinetics of a conjugated equine estrogen preparation (premarin) and a synthetic mixture of estrogens (C.E.S.) in postmenopausal women. J Soc Gynecol Investig 2000; 7: 175-183.
37. Levrant S and Barnes R. Pharmacology of Estrogens. In: Lobo R, editors. Treatment of the Postmenopausal Women: Basic and Clinical Aspects. New York: Raven Press, Ltd.; 1994. p. 57-68.
38. Gao S, Hendrie HC, Hall KS and Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry 1998; 55: 809-815.
39. Ott A, Breteler MM, van Harskamp F, Stijnen T and Hofman A. Incidence and risk of dementia. The Rotterdam Study. Am J Epidemiol 1998; 147: 574-580.
40. Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, Dartigues JF, Kragh-Sorensen P, Baldereschi M, Brayne C, Lobo A, Martinez-Lage JM, Stijnen T and Hofman A. Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology 1999; 53: 1992-1997.
41. Asthana S, Craft S, Baker LD, Raskind MA, Birnbaum RS, Lofgreen CP, Veith RC and Plymate SR. Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer's disease: results of a placebo-controlled, double-blind, pilot study. Psychoneuroendocrinology 1999; 24: 657-677.
42. Scarabin P, Oger E, Plu-Bureau G and group obotEaTEs. Differential association of oral and transdermal oestrogen replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428-432.
43. Vongpatanasin W, Tuncel M, Wang Z, Arbique D, Mehrad B and Jialal I. Differential effects of oral versus transdermal estrogen replacement therapy on c-reactive protein in postmenopausal women. J Am Coll Cardiol 2003; 41: 1358-1363.
44. Manson JE, Bassuk SS, Harman SM, Brinton EA, Cedars MI, Lobo R, Merriam GR, Miller VM, Naftolin F and Santoro N. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006; 13: 139-147.
45. Wickelgren I. Estrogen research. Brain researchers try to salvage estrogen treatments. Science 2003; 302: 1138-1139.
46. Rogers J and Morrison JH. Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease. J Neurosci 1985; 5: 2801-2808.
47. Blessed G, Tomlinson BE and Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 1968; 114: 797-811.
48. Toran-Allerand CD, Miranda RC, Bentham WD, Sohrabji F, Brown TJ, Hochberg RB and MacLusky NJ. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A 1992; 89: 4668-4672.
49. Shughrue PJ and Merchenthaler I. Evidence for novel estrogen binding sites in the rat hippocampus. Neuroscience 2000; 99: 605-612.
50. Shughrue PJ, Scrimo PJ and Merchenthaler I. Estrogen binding and estrogen receptor characterization (ERalpha and ERbeta) in the cholinergic neurons of the rat basal forebrain. Neuroscience 2000; 96: 41-49.
51. Shughrue PJ and Merchenthaler I. Estrogen is more than just a "sex hormone": novel sites for estrogen action in the hippocampus and cerebral cortex. Front Neuroendocrinol 2000; 21: 95-101.
52. Shughrue PJ and Merchenthaler I. Distribution of estrogen receptor beta immunoreactivity in the rat central nervous system. J Comp Neurol 2001; 436: 64-81.
53. Stone D, Rozovsky I, Morgan T, Anderson C and Finch C. Increased synaptic sprouting in response to estrogen via an apolipoprotein E-dependent mechanism: implications for Alzheimer's disease. J Neurosci 1998; 18(9): 3180-3185.
54. Li C, Brake WG, Romeo RD, Dunlop JC, Gordon M, Buzescu R, Magarinos AM, Allen PB, Greengard P, Luine V and McEwen BS. Estrogen alters hippocampal dendritic spine shape and enhances synaptic protein immunoreactivity and spatial memory in female mice. Proc Natl Acad Sci U S A 2004; 101: 2185-2190.
55. McEwen BS and Woolley CS. Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain. Exp Gerontol 1994; 29: 431-436.
56. Woolley CS and McEwen BS. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J Neurosci 1992; 12: 2549-2554.
57. Hao J, Janssen WG, Tang Y, Roberts JA, McKay H, Lasley B, Allen PB, Greengard P, Rapp PR, Kordower JH, Hof PR and Morrison JH. Estrogen increases the number of spinophilin-immunoreactive spines in the hippocampus of young and aged female rhesus monkeys. J Comp Neurol 2003; 465: 540-550.
58. Sakamoto H, Mezaki Y, Shikimi H, Ukena K and Tsutsui K. Dendritic growth and spine formation in response to estrogen in the developing Purkinje cell. Endocrinology 2003; 144: 4466-4477.
59. Znamensky V, Akama KT, McEwen BS and Milner TA. Estrogen levels regulate the subcellular distribution of phosphorylated Akt in hippocampal CA1 dendrites. J Neurosci 2003; 23: 2340-2347.
60. Rune GM, Wehrenberg U, Prange-Kiel J, Zhou L, Adelmann G and Frotscher M. Estrogen up-regulates estrogen receptor alpha and synaptophysin in slice cultures of rat hippocampus. Neuroscience 2002; 113: 167-175.
61. Tang Y, Janssen WG, Hao J, Roberts JA, McKay H, Lasley B, Allen PB, Greengard P, Rapp PR, Kordower JH, Hof PR and Morrison JH. Estrogen replacement increases spinophilin-immunoreactive spine number in the prefrontal cortex of female rhesus monkeys. Cereb Cortex 2004; 14: 215-223.
62. Sandstrom NJ and Williams CL. Memory retention is modulated by acute estradiol and progesterone replacement. Behav Neurosci 2001; 115: 384-393.
63. Pechenino AS and Frick KM. The effects of acute 17beta-estradiol treatment on gene expression in the young female mouse hippocampus. Neurobiol Learn Mem 2008;
64. Takuma K, Matsuo A, Himeno Y, Hoshina Y, Ohno Y, Funatsu Y, Arai S, Kamei H, Mizoguchi H, Nagai T, Koike K, Inoue M and Yamada K. 17beta-estradiol attenuates hippocampal neuronal loss and cognitive dysfunction induced by chronic restraint stress in ovariectomized rats. Neuroscience 2007; 146: 60-68.
65. van Amelsvoort T, Compton J and Murphy D. In vivo assessment of the effects of estrogen on human brain. Trends Endocrinol Metab 2001; 12: 273-276.
66. Yaffe K. Estrogens, selective estrogen receptor modulators, and dementia: what is the evidence? Ann N Y Acad Sci 2001; 949: 215-222.
67. Henderson VW. Cognitive changes after menopause: influence of estrogen. Clin Obstet Gynecol 2008; 51: 618-626.
68. Tinkler GP, Tobin JR and Voytko ML. Effects of two years of estrogen loss or replacement on nucleus basalis cholinergic neurons and cholinergic fibers to the dorsolateral prefrontal and inferior parietal cortex of monkeys.
69. Matsuda Y, Hirano H and Watanabe Y. Effects of estrogen on acetylcholine release in frontal cortex of female rats: involvement of serotonergic neuronal systems.
70. Nakazawa K and Ohno Y. Modulation by estrogens and xenoestrogens of recombinant human neuronal nicotinic receptors.
71. Daniel JM and Dohanich GP. Acetylcholine mediates the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and the associated improvement in working memory.
72. Gibbs RB. Oestrogen and the cholinergic hypothesis: implications for oestrogen replacement therapy in postmenopausal women. Review 37 refs.
73. Gibbs RB, Hashash A and Johnson DA. Effects of estrogen on potassium-stimulated acetylcholine release in the hippocampus and overlying cortex of adult rats.
74. Simpkins JW, Singh M and Bishop J. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol Aging 1994; 15 Suppl 2: S195-197.
75. Osterlund MK, Halldin C and Hurd YL. Effects of chronic 17beta-estradiol treatment on the serotonin 5-HT(1A) receptor mRNA and binding levels in the rat brain. Synapse 2000; 35: 39-44.
76. Mossner R, Schmitt A, Syagailo Y, Gerlach M, Riederer P and Lesch KP. The serotonin transporter in Alzheimer's and Parkinson's disease. J Neural Transm Suppl 2000; 345-350.
77. Cyr M, Landry M and Di Paolo T. Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology 2000; 23(1): 69-78.
78. Sawada H and Shimohama S. Neuroprotective effects of estradiol in mesencephalic dopaminergic neurons. Neurosci Biobehav Rev 2000; 24: 143-147.
79. Sawada H, Ibi M, Kihara T, Urushitani M, Honda K, Nakanishi M, Akaike A and Shimohama S. Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. Faseb J 2000; 14: 1202-1214.
80. Sweet RA, Hamilton RL, Healy MT, Wisniewski SR, Henteleff R, Pollock BG, Lewis DA and DeKosky ST. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol 2001; 58: 466-472.
81. Barbanti P, Fabbrini G, Ricci A, Bruno G, Cerbo R, Bronzetti E, Amenta F and Luigi Lenzi G. Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease. Mech Ageing Dev 2000; 120: 65-75.
82. Kim YJ, Hur EM, Park TJ and Kim KT. Nongenomic inhibition of catecholamine secretion by 17beta-estradiol in PC12 cells. J Neurochem 2000; 74: 2490-2496.
83. Menozzi R, Cagnacci A, Zanni AL, Bondi M, Volpe A and Del Rio G. Sympathoadrenal response of postmenopausal women prior and during prolonged administration of estradiol. Maturitas 2000; 34: 275-281.
84. Komesaroff PA, Esler MD and Sudhir K. Estrogen supplementation attenuates glucocorticoid and catecholamine responses to mental stress in perimenopausal women. J Clin Endocrinol Metab 1999; 84: 606-610.
85. Dayas CV, Xu Y, Buller KM and Day TA. Effects of chronic oestrogen replacement on stress-induced activation of hypothalamic-pituitary-adrenal axis control pathways.
86. Struble RG, Cady C, Nathan BP and McAsey M. Apolipoprotein E may be a critical factor in hormone therapy neuroprotection. Front Biosci 2008; 13: 5387-5405.
87. Horsburgh K, McCarron MO, White F and Nicoll JA. The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: evidence of common mechanisms and utility of animal models. Neurobiol Aging 2000; 21: 245-255.
88. McCullough LD and Hurn PD. Estrogen and ischemic neuroprotection: an integrated view. Trends Endocrinol Metab 2003; 14: 228-235.
89. Li R, Shen Y, Yang LB, Lue LF, Finch C and Rogers J. Estrogen enhances uptake of amyloid beta-protein by microglia derived from the human cortex. J Neurochem 2000; 75: 1447-1454.
90. Xu H, Gouras GK, Greenfield JP, Vincent B, Naslund J, Mazzarelli L, Fried G, Jovanovic JN, Seeger M, Relkin NR, Liao F, Checler F, Buxbaum JD, Chait BT, Thinakaran G, Sisodia SS, Wang R, Greengard P and Gandy S. Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med 1998; 4: 447-451.
91. Tang M, Abplanalp W, Ayres S and Subbiah MT. Superior and distinct antioxidant effects of selected estrogen metabolites on lipid peroxidation. Metabolism 1996; 45: 411-414.
92. Paganini-Hill A. Estrogen replacement therapy and stroke. Prog Cardiovasc Dis 1995; 38: 223-242.
93. McAsey ME, Cady C, Jackson LM, Li M, Randall S, Nathan BP and Struble RG. Time course of response to estradiol replacement in ovariectomized mice: brain apolipoprotein E and synaptophysin transiently increase and glial fibrillary acidic protein is suppressed. Exp Neurol 2006; 197: 197-205.
94. Thomas T, Bryant M, Clark L, Garces A and Rhodin J. Estrogen and raloxifene activities on amyloid-beta-induced inflammatory reaction. Microvascular Research. 2001; 61: 28-39.
95. Lin MT and Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443: 787-795.
96. Murphy AN, Fiskum G and Beal MF. Mitochondria in neurodegeneration: bioenergetic function in cell life and death. J Cereb Blood Flow Metab 1999; 19: 231-245.
97. Selkoe DJ. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol 1994; 53: 438-447.
98. Yue X, Lu M, Lancaster T, Cao P, Honda S, Staufenbiel M, Harada N, Zhong Z, Shen Y and Li R. Brain estrogen deficiency accelerates Abeta plaque formation in an Alzheimer's disease animal model. Proc Natl Acad Sci U S A 2005; 102: 19198-19203.
99. Sundermann EE, Gilbert PE and Murphy C. The effect of hormone therapy on olfactory sensitivity is dependent on apolipoprotein E genotype. Horm Behav 2008; 54: 528-533.
100. Lambert JC, Coyle N and Lendon C. The allelic modulation of apolipoprotein E expression by oestrogen: potential relevance for Alzheimer's disease.
101. Rozovsky I, Hoving S, Anderson CP, O'Callaghan J and Finch CE. Equine estrogens induce apolipoprotein E and glial fibrillary acidic protein in mixed glial cultures.
102. Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D and Paul SM. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2000; 97: 2892-2897.
103. Yaffe K, Haan M, Byers A, Tangen C and Kuller L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology 2000; 54: 1949-1954.
104. Wang JM, Irwin RW and Brinton RD. Activation of estrogen receptor alpha increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo. Proc Natl Acad Sci U S A 2006; 103: 16983-16988.
105. Kaplitt M, Gouras GK, Makimura H, Jovanovic J, Sweeney D, Greengard P, Relkin NR and Gandy S. Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications. Ann N Y Acad Sci 1996; 802: 42-49.
106. Mahley RW, Weisgraber KH and Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 2006; 103: 5644-5651.
107. Geary GG, McNeill AM, Ospina JA, Krause DN, Korach KS and Duckles SP. Selected contribution: cerebrovascular nos and cyclooxygenase are unaffected by estrogen in mice lacking estrogen receptor-alpha. J Appl Physiol 2001; 91: 2391-2399; discussion 2389-2390.
108. Gingerich S and Krukoff TL. Estrogen modulates endothelial and neuronal nitric oxide synthase expression via an estrogen receptor beta-dependent mechanism in hypothalamic slice cultures. Endocrinology 2005; 146: 2933-2941.
109. Zhao L and Brinton RD. Estrogen receptor alpha and beta differentially regulate intracellular Ca(2+) dynamics leading to ERK phosphorylation and estrogen neuroprotection in hippocampal neurons. Brain Res 2007; 1172: 48-59.
110. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC and Bender JR. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 2000; 87: 677-682.
111. Simoncini T, Rabkin E and Liao JK. Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 198-203.
112. Stirone C, Boroujerdi A, Duckles SP and Krause DN. Estrogen receptor activation of phosphoinositide-3 kinase, akt, and nitric oxide signaling in cerebral blood vessels: rapid and long-term effects. Mol Pharmacol 2005; 67: 105-113.
113. Chen DB, Bird IM, Zheng J and Magness RR. Membrane estrogen receptor-dependent extracellular signal-regulated kinase pathway mediates acute activation of endothelial nitric oxide synthase by estrogen in uterine artery endothelial cells. Endocrinology 2004; 145: 113-125.
114. Salom JB, Burguete MC, Perez-Asensio FJ, Centeno JM, Torregrosa G and Alborch E. Acute relaxant effects of 17-beta-estradiol through non-genomic mechanisms in rabbit carotid artery. Steroids 2002; 67: 339-346.
115. Salom JB, Burguete MC, Perez-Asensio FJ, Torregrosa G and Alborch E. Relaxant effects of 17-beta-estradiol in cerebral arteries through Ca(2+) entry inhibition. J Cereb Blood Flow Metab 2001; 21: 422-429.
116. Tsang SY, Yao X, Chan HY, Chen ZY, Ming WC and Huang Y. Effect of 17beta-estradiol exposure on vasorelaxation induced by K(+) channel openers and Ca(2+) channel blockers. Pharmacology 2002; 65: 26-31.
117. Stirone C, Duckles SP and Krause DN. Multiple forms of estrogen receptor-alpha in cerebral blood vessels: regulation by estrogen. Am J Physiol Endocrinol Metab 2003; 284: E184-192.
118. Penotti M, Nencioni T, Gabrielli L, Farina M, Castiglioni E and Polvani F. Blood flow variations in internal carotid and middle cerebral arteries induced by postmenopausal hormone replacement therapy. Am J Obstet Gynecol 1993; 169: 1226-1232.
119. de Kleijn MJ, Wilmink HW, Bots ML, Bak AA, van der Schouw YT, Planellas J, Engelen S, Banga JD and Grobbee DE. Hormone replacement therapy and endothelial function. Results of a randomized controlled trial in healthy postmenopausal women. Atherosclerosis 2001; 159: 357-365.
120. Wakatsuki A, Okatani Y, Ikenoue N and Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 2001; 104: 1773-1778.
121. Hashimoto M, Akishita M, Eto M, Ishikawa M, Kozaki K, Toba K, Sagara Y, Taketani Y, Orimo H and Ouchi Y. Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 1995; 92: 3431-3435.
122. Kawano H, Yasue H, Hirai N, Yoshida T, Fukushima H, Miyamoto S, Kojima S, Hokamaki J, Nakamura H, Yodoi J and Ogawa H. Effects of transdermal and oral estrogen supplementation on endothelial function, inflammation and cellular redox state. Int J Clin Pharmacol Ther 2003; 41: 346-353.
123. Kublickiene K, Svedas E, Landgren BM, Crisby M, Nahar N, Nisell H and Poston L. Small artery endothelial dysfunction in postmenopausal women: in vitro function, morphology, and modification by estrogen and selective estrogen receptor modulators. J Clin Endocrinol Metab 2005; 90: 6113-6122.
124. Chambliss KL and Shaul PW. Estrogen modulation of endothelial nitric oxide synthase. Endocr Rev 2002; 23: 665-686.
125. McNeill AM, Zhang C, Stanczyk FZ, Duckles SP and Krause DN. Estrogen increases endothelial nitric oxide synthase via estrogen receptors in rat cerebral blood vessels: effect preserved after concurrent treatment with medroxyprogesterone acetate or progesterone. Stroke 2002; 33: 1685-1691.
126. Pelligrino DA, Ye S, Tan F, Santizo RA, Feinstein DL and Wang Q. Nitric-oxide-dependent pial arteriolar dilation in the female rat: effects of chronic estrogen depletion and repletion. Biochem Biophys Res Commun 2000; 269: 165-171.
127. Skarsgard P, van Breemen C and Laher I. Estrogen regulates myogenic tone in pressurized cerebral arteries by enhanced basal release of nitric oxide. Am J Physiol 1997; 273: H2248-2256.
128. Sobey CG, Weiler JM, Boujaoude M and Woodman OL. Effect of short-term phytoestrogen treatment in male rats on nitric oxide-mediated responses of carotid and cerebral arteries: comparison with 17beta-estradiol. J Pharmacol Exp Ther 2004; 310: 135-140.
129. Stirone C, Chu Y, Sunday L, Duckles SP and Krause DN. 17 Beta-estradiol increases endothelial nitric oxide synthase mRNA copy number in cerebral blood vessels: quantification by real-time polymerase chain reaction. Eur J Pharmacol 2003; 478: 35-38.
130. Geary GG, Krause DN and Duckles SP. Estrogen reduces myogenic tone through a nitric oxide-dependent mechanism in rat cerebral arteries. Am J Physiol 1998; 275: H292-300.
131. Geary GG, Krause DN and Duckles SP. Gonadal hormones affect diameter of male rat cerebral arteries through endothelium-dependent mechanisms. Am J Physiol Heart Circ Physiol 2000; 279: H610-618.
132. Geary GG, Krause DN and Duckles SP. Estrogen reduces mouse cerebral artery tone through endothelial NOS- and cyclooxygenase-dependent mechanisms. Am J Physiol Heart Circ Physiol 2000; 279: H511-519.
133. Grohe C, Kann S, Fink L, Djoufack PC, Paehr M, van Eickels M, Vetter H, Meyer R and Fink KB. 17 Beta-estradiol regulates nNOS and eNOS activity in the hippocampus. Neuroreport 2004; 15: 89-93.
134. Pelligrino DA, Santizo R, Baughman VL and Wang Q. Cerebral vasodilating capacity during forebrain ischemia: effects of chronic estrogen depletion and repletion and the role of neuronal nitric oxide synthase. Neuroreport 1998; 9: 3285-3291.
135. Ospina JA, Duckles SP and Krause DN. 17beta-estradiol decreases vascular tone in cerebral arteries by shifting COX-dependent vasoconstriction to vasodilation. Am J Physiol Heart Circ Physiol 2003; 285: H241-250.
136. Ospina JA, Krause DN and Duckles SP. 17beta-estradiol increases rat cerebrovascular prostacyclin synthesis by elevating cyclooxygenase-1 and prostacyclin synthase. Stroke 2002; 33: 600-605.
137. Li X, Geary GG, Gonzales RJ, Krause DN and Duckles SP. Effect of estrogen on cerebrovascular prostaglandins is amplified in mice with dysfunctional NOS. Am J Physiol Heart Circ Physiol 2004; 287: H588-594.
138. Chrissobolis S, Budzyn K, Marley PD and Sobey CG. Evidence that estrogen suppresses rho-kinase function in the cerebral circulation in vivo. Stroke 2004; 35: 2200-2205.
139. Shay J, Futo J, Badrov N and Moss J. Estrogen withdrawal selectively increases serotonin reactivity in rabbit basilar artery. Life Sci 1994; 55: 1071-1081.
140. Zhang F, Ram JL, Standley PR and Sowers JR. 17 beta-Estradiol attenuates voltage-dependent Ca2+ currents in A7r5 vascular smooth muscle cell line. Am J Physiol 1994; 266: C975-980.
141. Chen JQ, Eshete M, Alworth WL and Yager JD. Binding of MCF-7 cell mitochondrial proteins and recombinant human estrogen receptors alpha and beta to human mitochondrial DNA estrogen response elements. J Cell Biochem 2004; 93: 358-373.
142. Stirone C, Duckles SP, Krause DN and Procaccio V. Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Mol Pharmacol 2005; 68: 959-965.
143. Nilsen J, Chen S, Irwin RW, Iwamoto S and Brinton RD. Estrogen protects neuronal cells from amyloid beta-induced apoptosis via regulation of mitochondrial proteins and function. BMC Neurosci 2006; 7: 74.
144. Nilsen J and Brinton RD. Mitochondria as therapeutic targets of estrogen action in the central nervous system. Curr Drug Targets CNS Neurol Disord 2004; 3: 297-313.
145. Ono H, Sasaki Y, Bamba E, Seki J, Giddings JC and Yamamoto J. Cerebral thrombosis and microcirculation of the rat during the oestrous cycle and after ovariectomy. Clin Exp Pharmacol Physiol 2002; 29: 73-78.
146. Ospina JA, Brevig HN, Krause DN and Duckles SP. Estrogen suppresses IL-1beta-mediated induction of COX-2 pathway in rat cerebral blood vessels. Am J Physiol Heart Circ Physiol 2004; 286: H2010-2019.
147. Sunday L, Tran MM, Krause DN and Duckles SP. Estrogen and progestagens differentially modulate vascular proinflammatory factors. Am J Physiol Endocrinol Metab 2006; 291: E261-267.
148. Sunday L, Osuna C, Krause DN and Duckles SP. Age alters cerebrovascular inflammation and effects of estrogen. Am J Physiol Heart Circ Physiol 2007; 292: H2333-2340.
149. Johnson AB, Bake S, Lewis DK and Sohrabji F. Temporal expression of IL-1beta protein and mRNA in the brain after systemic LPS injection is affected by age and estrogen. J Neuroimmunol 2006; 174: 82-91.
150. Chambliss KL and Shaul PW. Rapid activation of endothelial NO synthase by estrogen: evidence for a steroid receptor fast-action complex (SRFC) in caveolae. Steroids 2002; 67: 413-419.
151. Chambliss KL, Yuhanna IS, Anderson RG, Mendelsohn ME and Shaul PW. ERbeta has nongenomic action in caveolae. Mol Endocrinol 2002; 16: 938-946.
152. Haynes MP, Li L, Russell KS and Bender JR. Rapid vascular cell responses to estrogen and membrane receptors. Vascul Pharmacol 2002; 38: 99-108.
153. Levin ER. Cellular functions of plasma membrane estrogen receptors. Steroids 2002; 67: 471-475.
154. Chambliss KL, Simon L, Yuhanna IS, Mineo C and Shaul PW. Dissecting the basis of nongenomic activation of endothelial nitric oxide synthase by estradiol: role of ERalpha domains with known nuclear functions. Mol Endocrinol 2005; 19: 277-289.
155. Pietras RJ, Levin ER and Szego CM. Estrogen receptors and cell signaling. Science 2005; 310: 51-53; author reply 51-53.
156. Ho KJ and Liao JK. Nonnuclear actions of estrogen. Arterioscler Thromb Vasc Biol 2002; 22: 1952-1961.
157. Florian M, Lu Y, Angle M and Magder S. Estrogen induced changes in Akt-dependent activation of endothelial nitric oxide synthase and vasodilation. Steroids 2004; 69: 637-645.
158. Momoi H, Ikomi F and Ohhashi T. Estrogen-induced augmentation of endothelium-dependent nitric oxide-mediated vasodilation in isolated rat cerebral small arteries. Jpn J Physiol 2003; 53: 193-203.
159. Watanabe Y, Littleton-Kearney MT, Traystman RJ and Hurn PD. Estrogen restores postischemic pial microvascular dilation. Am J Physiol Heart Circ Physiol 2001; 281: H155-160.
160. Hu L, Yue Y, Zuo PP, Jin ZY, Feng F, You H, Li ML and Ge QS. Evaluation of neuroprotective effects of long-term low dose hormone replacement therapy on postmenopausal women brain hippocampus using magnetic resonance scanner. Chin Med Sci J 2006; 21: 214-218.
161. Yue Y, Hu L, Tian QJ, Jiang JM, Dong YL, Jin ZY, Cheng YH, Hong X, Ge QS and Zuo PP. Effects of long-term, low-dose sex hormone replacement therapy on hippocampus and cognition of postmenopausal women of different apoE genotypes. Acta Pharmacol Sin 2007; 28: 1129-1135.
162. McEwen B. Estrogen actions throughout the brain. Recent Prog Horm Res 2002; 57: 357-384.
163. Gresack JE and Frick KM. Effects of continuous and intermittent estrogen treatments on memory in aging female mice. Brain Res 2006; 1115: 135-147.
164. Rissanen A, Puolivali J, van Groen T and Riekkinen P, Jr. In mice tonic estrogen replacement therapy improves non-spatial and spatial memory in a water maze task. Neuroreport 1999; 10: 1369-1372.
165. Gresack JE and Frick KM. Post-training estrogen enhances spatial and object memory consolidation in female mice. Pharmacol Biochem Behav 2006; 84: 112-119.
166. Liu XA, Zhu LQ, Zhang Q, Shi HR, Wang SH, Wang Q and Wang JZ. Estradiol attenuates tau hyperphosphorylation induced by upregulation of protein kinase-A. Neurochem Res 2008; 33: 1811-1820.
167. Asthana S, Baker L, Craft S, Lofgreen C, Avery E, Raskind M, Cherrier M, Wong M, Veith R and Plymate S. Estrogen-induced enhancement in memory in postmenopausal women with Alzheimer's disease. Neurobiol Aging 1998; 19(4S): Abstract# 748, page S178.
168. Honjo H, Ogino Y, Tanaka K, Urabe M, Kashiwagi T, Ishihara S, Okada H, Araki K, Fushiki S, Nakajima K, Hayashi K, Hayashi M and Sakaki T. An effect of conjugated estrogen to cognitive impairment in women with senile dementia-Alzheimer's type: A placebo-controlled, double-blind study. J Jpn Menopause Soc 1993; 1: 167-171.
169. Brookmeyer R, Gray S and Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-1342.
170. Morrison JH, Brinton RD, Schmidt PJ and Gore AC. Estrogen, menopause, and the aging brain: how basic neuroscience can inform hormone therapy in women. J Neurosci 2006; 26: 10332-10348.